



Press release

**Deinove S.A. announces the registration of its Document de Base with the
Autorité des marchés financiers (AMF), the French market authority, in the
context of the Company's contemplated initial public offering on the
Alternext market of NYSE Euronext Paris**

Paris, March 26 2010 – [Deinove](#), the world's leading specialist in the application of deinococci bacteria to biofuels, green chemistry and antibiotics, announced the registration of its Document de Base with the "Autorité des Marchés Financiers" (AMF) under number I.10-014 on March 25th, 2010. This is a key step towards the company's contemplated initial public offering on the Alternext market of NYSE Euronext, Paris.

The company is developing breakthrough technologies by leveraging the exceptional biodiversity and robustness of the deinococci (natural bacteria that have been on Earth for over 3 billion years) to elaborate innovative industrial processes – particularly for bioethanol production from biomass and bio-derived waste.

Filing of the Document de Base is the first step towards an initial public offering of Deinove's shares on NYSE Euronext Paris, which is expected to take place subject to market conditions after approval of the offer prospectus by the AMF.

###

About Deinove

The biotech company Deinove is dedicated to the development and commercial exploitation of innovative technological processes for the production of biofuels and other compounds of industrial or pharmaceutical interest by exploiting the deinococci's exceptional natural properties. Deinove intends to leverage its proprietary bacterial strains, technologies and processes by outlicensing to industrial partners.

The Paris-based biotech company, which currently has 15 employees, was incorporated in late 2006 under the joint impetus of Philippe Pouletty MD (Managing Partner at the private equity firm Truffle Capital) and Miroslav Radman PhD, one of world's leading molecular biologists and a member of the French Academy of Science. Professor Radman elucidated and patented the genetic mechanism behind the extraordinary biodiversity and robustness of the bacterium *Deinococcus*, on which Deinove's innovative strategy is based.

For further information, visit www.deinove.com

**Not for direct or indirect distribution in the United States of America,
Canada, Australia or Japan**

Availability of the document de base

The document de base registered on March 25th, 2010 under number I.10-014 is available, free of charge and on demand, from Deinove S.A., 4 rue Tesson Paris 75010, France, and on the websites of the "Autorité des Marchés Financiers" (www.amf-france.org) and Deinove (www.deinove.com).

Risk factors

Deinove draws the attention of the public to the section entitled "Risk Factors" in its document de base registered with the "Autorité des Marchés Financiers". These risk factors are discussed in detail in Chapter 4 of the document de base.

Notice

This announcement does not, and shall not under any circumstances, constitute a public offering or an invitation to the public in connection with any offer of securities. No public offering of securities will be conducted in France or abroad prior to the delivery by the AMF of a visa on a prospectus that complies with the provisions of Directive 2003/71/CE.

The publication of this press release in certain countries may violate applicable regulations. The information contained therein does not constitute an offer for securities in the United States, Canada, Australia or Japan or in any other jurisdiction. This press release should not be published, transmitted or distributed, directly or indirectly, into the United States, Canada, Australia or Japan.

This document is not an offer for sale of the shares of Deinove in the United States. The shares of Deinove may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Deinove does not intend to register any portion of the offering in the United States or to conduct a public offering of the shares in the United States.

This document contains forward-looking statements. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de base, changes in economic conditions, the financial markets or the markets in which Deinove operates.

Contacts

DEINOVE

Directeur général
Jacques Biton
Tél : + 33 (0) 1 42 03 27 90
jbiton@deinove.com

ALIZE RP

Press Relations
Caroline Carmagnol
+ 33 (0) 1 42 68 86 43 / 6 64 18 99 59
caroline@alizerp.com

ACTUS

Corinne Puissant
+ 33 (0) 1 53 67 36 57 / 6 72 93 13 78
cpuissant@actus.com